Fluvoxamine inhibits weight gain and food intake in food restricted hyperphagic wistar rats

Tomokazu Shinozaki, Masaki Kimura, Makoto Hosoyamada, Toshiaki Shibasaki

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)


The effects of fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), were studied in normophagic and food-restriction-induced hyperphagic middle-aged Wistar rats. Normophagic intact Wistar rats were given fluvoxamine (100 mg/kg/d, per os (p.o.)) or vehicle for 10 d. Hyperphagic middle-aged Wistar rats were subjected to 10 d of food restriction; they were allowed to refeed for 10 d, with ad libitum food access and administered fluvoxamine (100 mg/kg/d, p.o.) or vehicle during the 10-d refeeding period. Fluvoxamine administration to normophagic middle-aged Wistar rats affected neither their weight nor food intake. However, administration to food-restricted rats showed inhibitory effects of weight gain and food intake during 10 d of refeeding. Fluvoxamine-treated rats showed significantly lower neuropeptide Y (NPY) immunostaining levels in the paraventricular nucleus (PVN) and dorsomedial hypothalamic nucleus (DMH) than untreated controls. Hypophagic and weight-inhibiting effects of fluvoxamine might be mediated via decreased NPY in PVN and DMH. These results suggest that the appetite-controlling effect of fluvoxamine might be responsive to the rats' appetite condition.

Original languageEnglish
Pages (from-to)2250-2254
Number of pages5
JournalBiological and Pharmaceutical Bulletin
Issue number12
Publication statusPublished - 2008


  • 5-hydroxytryptamine
  • Appetite condition
  • Fluvoxamine
  • Neuropeptide y
  • Obesity

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science


Dive into the research topics of 'Fluvoxamine inhibits weight gain and food intake in food restricted hyperphagic wistar rats'. Together they form a unique fingerprint.

Cite this